Marcio Covas Moschovas, Assistant Professor at the University of Central Florida, shared a post on LinkedIn:
“Can a genomic test reveal aggressive prostate cancer that the biopsy misses?
Why it matters:
Biopsy undergrading remains one of the biggest challenges in prostate cancer. Some patients classified as low or intermediate risk may actually harbor Grade Group 5 disease, the most aggressive form of prostate cancer.
Going deeper:
In our recent study, we evaluated whether the Cell Cycle Progression (CCP) score could detect biologically aggressive tumors not identified at biopsy.
Key findings:
- About 7% of patients had Grade Group 5 disease despite biopsy showing lower-grade cancer
- The CCP genomic score independently predicted hidden aggressive disease
- Combining CCP with CAPRA clinical risk significantly improved predictive accuracy
- Patients with both high CCP and high CAPRA scores had a dramatically higher probability of GG5 at final pathology
The big picture:
Genomic profiling is helping us move closer to true precision medicine in prostate cancer.
By integrating molecular biology with clinical risk models, we can better identify patients who need treatment intensification, and reduce the risk of undertreating aggressive disease.
Title: Cell Cycle Progression Score Identifies Biopsy-Undetected Grade Group 5 Prostate Cancer
Authors: Yu Ozawa, Marcio Covas Moschovas, Marco Sandri, Rohan Sharma, Shady Saikali, Travis Rogers, Vipul Patel
Read the full article on WILEY.
Other articles featuring Marcio Covas Moschovas on OncoDaily.